Share Price and Basic Stock Data
Last Updated: November 14, 2025, 10:38 pm
| PEG Ratio | 1.04 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Unichem Laboratories Ltd operates within the pharmaceuticals sector, focusing on the development and manufacture of a wide array of generic and branded formulations. The company’s revenue trajectory has shown a positive trend, with reported sales increasing from ₹1,270 Cr in March 2022 to ₹1,343 Cr in March 2023. For the fiscal year ending March 2025, sales are projected to rise further to ₹2,111 Cr, reflecting a robust growth strategy. Quarterly sales figures indicate a consistent upward movement, peaking at ₹533 Cr in December 2024. However, the company faced challenges in earlier quarters, with operating profits fluctuating and even reporting negative figures in several quarters of FY 2023. The sales increase in FY 2024 to ₹1,785 Cr signifies recovery and an enhanced market position, driven by improved product offerings and market penetration. Overall, the revenue growth is underpinned by strategic initiatives aimed at expanding Unichem’s footprint in both domestic and international markets.
Profitability and Efficiency Metrics
Unichem Laboratories has demonstrated a mixed performance in profitability metrics over the past fiscal years. The operating profit margin (OPM) stood at 6% in March 2024, improving from a negative OPM of 3% in March 2023. The net profit margin also saw a notable recovery, rising to 6.51% in March 2025, after grappling with losses in previous years. The company’s net profit recorded a significant turnaround, moving from a loss of ₹202 Cr in March 2023 to a profit of ₹138 Cr in March 2025. The return on equity (ROE) reported at 5.59% indicates moderate efficiency in generating returns for shareholders relative to equity. However, the cash conversion cycle (CCC) of 382 days suggests inefficiencies in managing receivables and inventory. This high CCC could potentially hinder liquidity and operational efficiency, which is critical for maintaining competitive advantage in the fast-paced pharmaceuticals sector.
Balance Sheet Strength and Financial Ratios
Unichem Laboratories maintains a relatively stable balance sheet, with total assets amounting to ₹3,569 Cr as of March 2025. The company’s total liabilities stood at ₹3,569 Cr, indicating a moderate leverage position with total debt to equity at 0.17x, which is manageable compared to industry standards. The company reported reserves of ₹2,437 Cr, providing a solid base for future investments and operational needs. The interest coverage ratio (ICR) of 14.27x highlights Unichem’s ability to meet interest obligations comfortably, reflecting sound financial health. Additionally, the price-to-book value (P/BV) ratio at 1.99x suggests that the stock is trading at a premium relative to its book value, which may signal investor confidence. However, the reported decrease in cash earnings in recent periods raises concerns about liquidity, which could restrict operational flexibility and growth potential.
Shareholding Pattern and Investor Confidence
The shareholding structure of Unichem Laboratories reflects a stable yet evolving investor landscape. Promoter ownership stood at 70.22% as of March 2025, indicating strong control and commitment from the founding family. Institutional investment, comprising Foreign Institutional Investors (FIIs) at 0.99% and Domestic Institutional Investors (DIIs) at 10.74%, suggests a cautious but present institutional interest in the company. The public shareholding comprises 18.04%, with a total of 23,577 shareholders, reflecting a diversified ownership base. The increase in promoter holding from 50.94% in December 2022 to the current level indicates confidence in the company’s future prospects. However, the low FII participation could be a concern, suggesting that broader market confidence may still be developing. The shareholding dynamics indicate a solid foundation but also highlight areas where increased institutional interest could enhance market perception and support future growth.
Outlook, Risks, and Final Insight
Looking ahead, Unichem Laboratories is poised for growth, driven by expanding sales and improving profitability metrics. However, several risks linger, including high inventory days and cash conversion cycle, which could affect liquidity and operational efficiency. The company’s ability to maintain its upward revenue trajectory while managing costs effectively will be crucial. Additionally, external factors such as regulatory changes and competitive pressures in the pharmaceuticals sector could impact performance. On the positive side, the strong promoter backing and stable financial ratios provide a robust platform for future initiatives. If Unichem can successfully streamline its operations and enhance its market strategies, it may capitalize on growth opportunities, especially in emerging markets. Conversely, failure to address operational inefficiencies could hinder profitability and investor confidence, impacting its market position significantly.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Unichem Laboratories Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 147 Cr. | 117 | 247/84.3 | 32.6 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.52 Cr. | 1.84 | 4.33/1.82 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,854 Cr. | 446 | 479/192 | 101 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.1 Cr. | 45.9 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 38.1 Cr. | 26.0 | 29.1/17.0 | 90.6 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,345.90 Cr | 1,190.20 | 55.77 | 201.41 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 310 | 329 | 302 | 402 | 423 | 416 | 466 | 432 | 483 | 507 | 533 | 587 | 527 |
| Expenses | 311 | 347 | 345 | 386 | 395 | 407 | 435 | 406 | 443 | 452 | 448 | 503 | 504 |
| Operating Profit | -1 | -18 | -43 | 16 | 28 | 9 | 31 | 25 | 40 | 55 | 86 | 84 | 22 |
| OPM % | -0% | -6% | -14% | 4% | 7% | 2% | 7% | 6% | 8% | 11% | 16% | 14% | 4% |
| Other Income | 8 | 4 | 16 | -28 | 9 | 6 | 79 | -119 | 4 | 9 | 14 | 9 | 7 |
| Interest | 3 | 5 | 4 | 6 | 6 | 7 | 6 | 5 | 4 | 5 | 7 | 5 | 7 |
| Depreciation | 25 | 28 | 31 | 30 | 29 | 29 | 32 | 27 | 32 | 32 | 31 | 30 | 32 |
| Profit before tax | -21 | -47 | -61 | -47 | 2 | -22 | 73 | -126 | 8 | 27 | 62 | 58 | -9 |
| Tax % | 13% | 50% | 4% | -6% | 132% | 12% | -0% | 3% | 74% | 9% | 6% | 8% | 16% |
| Net Profit | -23 | -71 | -64 | -44 | -1 | -24 | 73 | -129 | 2 | 25 | 58 | 53 | -10 |
| EPS in Rs | -3.32 | -10.04 | -9.08 | -6.29 | -0.10 | -3.48 | 10.40 | -18.37 | 0.29 | 3.50 | 8.22 | 7.52 | -1.49 |
Last Updated: August 20, 2025, 1:50 am
Below is a detailed analysis of the quarterly data for Unichem Laboratories Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 527.00 Cr.. The value appears to be declining and may need further review. It has decreased from 587.00 Cr. (Mar 2025) to 527.00 Cr., marking a decrease of 60.00 Cr..
- For Expenses, as of Jun 2025, the value is 504.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 503.00 Cr. (Mar 2025) to 504.00 Cr., marking an increase of 1.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 22.00 Cr.. The value appears to be declining and may need further review. It has decreased from 84.00 Cr. (Mar 2025) to 22.00 Cr., marking a decrease of 62.00 Cr..
- For OPM %, as of Jun 2025, the value is 4.00%. The value appears to be declining and may need further review. It has decreased from 14.00% (Mar 2025) to 4.00%, marking a decrease of 10.00%.
- For Other Income, as of Jun 2025, the value is 7.00 Cr.. The value appears to be declining and may need further review. It has decreased from 9.00 Cr. (Mar 2025) to 7.00 Cr., marking a decrease of 2.00 Cr..
- For Interest, as of Jun 2025, the value is 7.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.00 Cr. (Mar 2025) to 7.00 Cr., marking an increase of 2.00 Cr..
- For Depreciation, as of Jun 2025, the value is 32.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 30.00 Cr. (Mar 2025) to 32.00 Cr., marking an increase of 2.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -9.00 Cr.. The value appears to be declining and may need further review. It has decreased from 58.00 Cr. (Mar 2025) to -9.00 Cr., marking a decrease of 67.00 Cr..
- For Tax %, as of Jun 2025, the value is 16.00%. The value appears to be increasing, which may not be favorable. It has increased from 8.00% (Mar 2025) to 16.00%, marking an increase of 8.00%.
- For Net Profit, as of Jun 2025, the value is -10.00 Cr.. The value appears to be declining and may need further review. It has decreased from 53.00 Cr. (Mar 2025) to -10.00 Cr., marking a decrease of 63.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is -1.49. The value appears to be declining and may need further review. It has decreased from 7.52 (Mar 2025) to -1.49, marking a decrease of 9.01.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 4:13 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,133 | 1,202 | 1,333 | 698 | 815 | 1,180 | 1,104 | 1,235 | 1,270 | 1,343 | 1,785 | 2,111 | 2,226 |
| Expenses | 956 | 1,100 | 1,169 | 738 | 942 | 1,254 | 1,153 | 1,144 | 1,198 | 1,389 | 1,698 | 1,846 | 1,968 |
| Operating Profit | 178 | 101 | 164 | -41 | -128 | -74 | -49 | 91 | 72 | -46 | 87 | 265 | 258 |
| OPM % | 16% | 8% | 12% | -6% | -16% | -6% | -4% | 7% | 6% | -3% | 5% | 13% | 12% |
| Other Income | 83 | 20 | 15 | 184 | 2,735 | 91 | 91 | 50 | 47 | -0 | -26 | 35 | -8 |
| Interest | 3 | 3 | 3 | 3 | 8 | 8 | 8 | 5 | 6 | 17 | 23 | 21 | 27 |
| Depreciation | 46 | 41 | 39 | 44 | 51 | 67 | 82 | 84 | 91 | 113 | 123 | 125 | 123 |
| Profit before tax | 212 | 77 | 137 | 97 | 2,548 | -58 | -48 | 51 | 22 | -176 | -85 | 155 | 100 |
| Tax % | 20% | 3% | 21% | -12% | 0% | -59% | 25% | 33% | -50% | 15% | 10% | 11% | |
| Net Profit | 169 | 75 | 108 | 109 | 2,545 | -24 | -60 | 34 | 33 | -202 | -94 | 138 | 88 |
| EPS in Rs | 18.68 | 8.31 | 11.90 | 11.96 | 361.82 | -3.38 | -8.55 | 4.87 | 4.70 | -28.72 | -13.32 | 19.53 | 12.56 |
| Dividend Payout % | 43% | 24% | 17% | 25% | 1% | -118% | -47% | 82% | 85% | -14% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -55.62% | 44.00% | 0.93% | 2234.86% | -100.94% | -150.00% | 156.67% | -2.94% | -712.12% | 53.47% | 246.81% |
| Change in YoY Net Profit Growth (%) | 0.00% | 99.62% | -43.07% | 2233.94% | -2335.81% | -49.06% | 306.67% | -159.61% | -709.18% | 765.59% | 193.34% |
Unichem Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 14% |
| 3 Years: | 18% |
| TTM: | 20% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 29% |
| 3 Years: | 63% |
| TTM: | 651% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 15% |
| 3 Years: | 12% |
| 1 Year: | -13% |
| Return on Equity | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 0% |
| 3 Years: | -1% |
| Last Year: | 6% |
Last Updated: September 5, 2025, 1:50 pm
No data available for the Balance Sheet data table.
Cash Flow - No data available for this post.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 63 | 58 | 60 | 165 | 124 | 135 | 129 | 74 | 142 | 160 | 131 | 135 |
| Inventory Days | 192 | 171 | 184 | 397 | 278 | 278 | 374 | 518 | 527 | 414 | 365 | 418 |
| Days Payable | 142 | 114 | 131 | 297 | 230 | 182 | 236 | 202 | 161 | 193 | 174 | 170 |
| Cash Conversion Cycle | 113 | 116 | 113 | 265 | 172 | 231 | 267 | 390 | 508 | 382 | 322 | 382 |
| Working Capital Days | 94 | 88 | 90 | 174 | 133 | 165 | 154 | 163 | 207 | 207 | 173 | 159 |
| ROCE % | 19% | 9% | 15% | 9% | 128% | -2% | -2% | 2% | 1% | -5% | -0% | 6% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Small Cap Fund - Regular Plan | 5,473,134 | 0.9 | 256.12 | 5,473,134 | 2025-04-22 17:25:16 | 0% |
| DSP Healthcare Fund | 735,591 | 1.58 | 34.42 | 735,591 | 2025-04-22 17:25:16 | 0% |
| Franklin India Opportunities Fund | 313,225 | 0.59 | 14.66 | 313,225 | 2025-04-22 17:25:17 | 0% |
| Motilal Oswal S&P BSE Healthcare ETF | 366 | 0.17 | 0.02 | 366 | 2025-04-22 17:25:17 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 19.53 | -10.01 | -28.72 | 4.70 | 4.88 |
| Diluted EPS (Rs.) | 19.53 | -10.01 | -28.72 | 4.70 | 4.88 |
| Cash EPS (Rs.) | 37.23 | 6.07 | -7.13 | 17.80 | 16.91 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 348.10 | 335.54 | 345.89 | 371.90 | 363.16 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 348.10 | 335.54 | 345.89 | 371.90 | 363.16 |
| Revenue From Operations / Share (Rs.) | 299.85 | 242.15 | 190.75 | 180.36 | 175.43 |
| PBDIT / Share (Rs.) | 42.64 | 18.73 | -0.99 | 17.09 | 20.07 |
| PBIT / Share (Rs.) | 24.95 | 2.64 | -17.11 | 4.14 | 8.09 |
| PBT / Share (Rs.) | 21.96 | -8.76 | -19.57 | 3.27 | 7.36 |
| Net Profit / Share (Rs.) | 19.53 | -10.01 | -23.25 | 4.85 | 4.92 |
| NP After MI And SOA / Share (Rs.) | 19.53 | -10.01 | -28.72 | 4.70 | 4.88 |
| PBDIT Margin (%) | 14.22 | 7.73 | -0.52 | 9.47 | 11.43 |
| PBIT Margin (%) | 8.31 | 1.09 | -8.97 | 2.29 | 4.61 |
| PBT Margin (%) | 7.32 | -3.61 | -10.26 | 1.81 | 4.19 |
| Net Profit Margin (%) | 6.51 | -4.13 | -12.18 | 2.68 | 2.80 |
| NP After MI And SOA Margin (%) | 6.51 | -4.13 | -15.05 | 2.60 | 2.77 |
| Return on Networth / Equity (%) | 5.61 | -2.98 | -8.30 | 1.26 | 1.34 |
| Return on Capital Employeed (%) | 6.81 | 0.75 | -4.71 | 1.05 | 2.17 |
| Return On Assets (%) | 3.85 | -2.22 | -6.33 | 0.99 | 1.09 |
| Long Term Debt / Equity (X) | 0.02 | 0.01 | 0.02 | 0.03 | 0.00 |
| Total Debt / Equity (X) | 0.17 | 0.09 | 0.12 | 0.12 | 0.03 |
| Asset Turnover Ratio (%) | 0.62 | 0.53 | 0.41 | 0.30 | 0.35 |
| Current Ratio (X) | 2.05 | 2.40 | 2.49 | 2.99 | 2.72 |
| Quick Ratio (X) | 1.06 | 1.40 | 1.51 | 1.90 | 1.66 |
| Inventory Turnover Ratio (X) | 1.05 | 1.12 | 0.86 | 0.87 | 1.15 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 85.18 | 82.04 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 22.66 | 23.72 |
| Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 14.82 | 17.96 |
| Cash Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 77.34 | 76.28 |
| Interest Coverage Ratio (X) | 14.27 | 5.82 | -0.40 | 19.70 | 27.60 |
| Interest Coverage Ratio (Post Tax) (X) | 7.54 | 0.43 | -8.45 | 6.59 | 7.77 |
| Enterprise Value (Cr.) | 5189.65 | 3504.16 | 2147.12 | 2049.28 | 2195.83 |
| EV / Net Operating Revenue (X) | 2.46 | 2.06 | 1.60 | 1.61 | 1.78 |
| EV / EBITDA (X) | 17.29 | 26.58 | -304.97 | 17.03 | 15.54 |
| MarketCap / Net Operating Revenue (X) | 2.31 | 2.02 | 1.52 | 1.44 | 1.76 |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 14.81 | 17.95 |
| Price / BV (X) | 1.99 | 1.46 | 0.83 | 0.70 | 0.85 |
| Price / Net Operating Revenue (X) | 2.31 | 2.02 | 1.52 | 1.44 | 1.76 |
| EarningsYield | 0.02 | -0.02 | -0.09 | 0.01 | 0.01 |
After reviewing the key financial ratios for Unichem Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 19.53. This value is within the healthy range. It has increased from -10.01 (Mar 24) to 19.53, marking an increase of 29.54.
- For Diluted EPS (Rs.), as of Mar 25, the value is 19.53. This value is within the healthy range. It has increased from -10.01 (Mar 24) to 19.53, marking an increase of 29.54.
- For Cash EPS (Rs.), as of Mar 25, the value is 37.23. This value is within the healthy range. It has increased from 6.07 (Mar 24) to 37.23, marking an increase of 31.16.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 348.10. It has increased from 335.54 (Mar 24) to 348.10, marking an increase of 12.56.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 348.10. It has increased from 335.54 (Mar 24) to 348.10, marking an increase of 12.56.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 299.85. It has increased from 242.15 (Mar 24) to 299.85, marking an increase of 57.70.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 42.64. This value is within the healthy range. It has increased from 18.73 (Mar 24) to 42.64, marking an increase of 23.91.
- For PBIT / Share (Rs.), as of Mar 25, the value is 24.95. This value is within the healthy range. It has increased from 2.64 (Mar 24) to 24.95, marking an increase of 22.31.
- For PBT / Share (Rs.), as of Mar 25, the value is 21.96. This value is within the healthy range. It has increased from -8.76 (Mar 24) to 21.96, marking an increase of 30.72.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 19.53. This value is within the healthy range. It has increased from -10.01 (Mar 24) to 19.53, marking an increase of 29.54.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 19.53. This value is within the healthy range. It has increased from -10.01 (Mar 24) to 19.53, marking an increase of 29.54.
- For PBDIT Margin (%), as of Mar 25, the value is 14.22. This value is within the healthy range. It has increased from 7.73 (Mar 24) to 14.22, marking an increase of 6.49.
- For PBIT Margin (%), as of Mar 25, the value is 8.31. This value is below the healthy minimum of 10. It has increased from 1.09 (Mar 24) to 8.31, marking an increase of 7.22.
- For PBT Margin (%), as of Mar 25, the value is 7.32. This value is below the healthy minimum of 10. It has increased from -3.61 (Mar 24) to 7.32, marking an increase of 10.93.
- For Net Profit Margin (%), as of Mar 25, the value is 6.51. This value is within the healthy range. It has increased from -4.13 (Mar 24) to 6.51, marking an increase of 10.64.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.51. This value is below the healthy minimum of 8. It has increased from -4.13 (Mar 24) to 6.51, marking an increase of 10.64.
- For Return on Networth / Equity (%), as of Mar 25, the value is 5.61. This value is below the healthy minimum of 15. It has increased from -2.98 (Mar 24) to 5.61, marking an increase of 8.59.
- For Return on Capital Employeed (%), as of Mar 25, the value is 6.81. This value is below the healthy minimum of 10. It has increased from 0.75 (Mar 24) to 6.81, marking an increase of 6.06.
- For Return On Assets (%), as of Mar 25, the value is 3.85. This value is below the healthy minimum of 5. It has increased from -2.22 (Mar 24) to 3.85, marking an increase of 6.07.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.17. This value is within the healthy range. It has increased from 0.09 (Mar 24) to 0.17, marking an increase of 0.08.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.62. It has increased from 0.53 (Mar 24) to 0.62, marking an increase of 0.09.
- For Current Ratio (X), as of Mar 25, the value is 2.05. This value is within the healthy range. It has decreased from 2.40 (Mar 24) to 2.05, marking a decrease of 0.35.
- For Quick Ratio (X), as of Mar 25, the value is 1.06. This value is within the healthy range. It has decreased from 1.40 (Mar 24) to 1.06, marking a decrease of 0.34.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.05. This value is below the healthy minimum of 4. It has decreased from 1.12 (Mar 24) to 1.05, marking a decrease of 0.07.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 14.27. This value is within the healthy range. It has increased from 5.82 (Mar 24) to 14.27, marking an increase of 8.45.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.54. This value is within the healthy range. It has increased from 0.43 (Mar 24) to 7.54, marking an increase of 7.11.
- For Enterprise Value (Cr.), as of Mar 25, the value is 5,189.65. It has increased from 3,504.16 (Mar 24) to 5,189.65, marking an increase of 1,685.49.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.46. This value is within the healthy range. It has increased from 2.06 (Mar 24) to 2.46, marking an increase of 0.40.
- For EV / EBITDA (X), as of Mar 25, the value is 17.29. This value exceeds the healthy maximum of 15. It has decreased from 26.58 (Mar 24) to 17.29, marking a decrease of 9.29.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.31. This value is within the healthy range. It has increased from 2.02 (Mar 24) to 2.31, marking an increase of 0.29.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 1.99. This value is within the healthy range. It has increased from 1.46 (Mar 24) to 1.99, marking an increase of 0.53.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.31. This value is within the healthy range. It has increased from 2.02 (Mar 24) to 2.31, marking an increase of 0.29.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from -0.02 (Mar 24) to 0.02, marking an increase of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Unichem Laboratories Ltd:
- Net Profit Margin: 6.51%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 6.81% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 5.61% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 7.54
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.06
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 22.6 (Industry average Stock P/E: 55.77)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.17
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 6.51%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 47, Kandivli Industrial Estate, Mumbai Maharashtra 400067 | shares@unichemlabs.com http://www.unichemlabs.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Prakash A Mody | Chairman, Non Ind & Non Exe Director |
| Mr. Pabitrakumar Bhattacharyya | Managing Director |
| Mr. Pranay Godha | Non Exe.Non Ind.Director |
| Ms. Priti Puri | Independent Director |
| Mr. Anand Kusre | Independent Director |
| Mr. Arun Todarwal | Independent Director |